Don ’ t Count on 23andMe to Detect Most Breast Cancer Risks, Study Warns

The DNA testing company, which has 10 million customers, misses nearly 90 percent of people with risky BRCA mutations. It says the criticism is overblown.

Source: NYT Health - April 16, 2019 Category: Consumer Health News Authors: HEATHER MURPHY Tags: Genetics and Heredity Tests (Medical) Breast Cancer DNA (Deoxyribonucleic Acid) Ovarian Cancer 23andMe Promethease (SNPedia) Invitae Corp. Source Type: news